VRDN:NASDAQViridian Therapeutics, Inc. Analysis

Viridian Therapeutics is trading at $16.61, well below its 20‑day (14.84), 50‑day (20.91) and 200‑day (24.32) simple moving averages, signaling a bearish price backdrop. The Relative Strength Index sits near neutral at 48.9, while the MACD line has crossed above its signal (-0.99 vs -1.85), generating a bullish histogram and a bullish MACD signal. The stock is anchored by a support level around $13.18 and faces resistance near $20, with a 30‑day volatility of an extreme 172% and a beta of 1.23, underscoring a highly volatile, high‑beta profile.
On the fundamentals side, VRDN reports negative earnings (trailing EPS -3.35) and a steep operating loss, yet it holds a robust cash cushion of $762 M against modest debt of $53 M (debt‑to‑equity ≈ 8.4). Analysts collectively rate the stock as a strong buy with a median price target of $33.5, implying an upside of over 100%. The upcoming PDUFA decision for its lead candidate Veligrotrug in June and a recent upsized public offering provide both a potential catalyst and additional runway, making the stock a high‑risk, high‑reward play.